Topics covered: Trend Toward Orphan Disease Drug Development, Ownership Ego Preventing Shareholder Returns, IPO And Secondary Offering Window Opening, Impact Of Health Care Reform, Heightened M&A Activity, Generic Drug Competition, Gene Delivery Technology, Easier Credit For Small Cap Biotech Companies, Developments In Cancer Chemotherapeutics, Decreased Clinical Development Risk, Current Length Of FDA Approval Process, Convergence Of Large-Cap Biotech And Pharmaceutical Companies, Big Pharma R&D Pipeline
